Clinical Trials at Yale University
As of September 2026, 229 paid clinical trials are recruiting at Yale University, located at 310 CEDAR ST, 416A LAUDER HALL, NEW HAVEN, CT 06510-3218, phone (203) 785-6843 in New Haven, Connecticut. Active studies at this site cover conditions such as Advanced Solid Tumor, Breast Cancer and Alcohol Use Disorder. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
View the full facility profile →
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
229 clinical trials at Yale University
·Clear filters·Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II
SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)
DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
DALY II USA/ MB-CART2019.1 for DLBCL
SELUTION4BTK Trial
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
INHALE-1st: Afrezza® For Youth With Newly-Diagnosed Type 1 Diabetes
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
RevCore for In Stent Thrombosis
The ArtixASCEND Study
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
The PERSEVERE Study
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
The Pivotal Study of RapidPulseTM Aspiration System
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
Terumo Aortic Global Endovascular Registry
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)
Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections
First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer
A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)
Common conditions studied in New Haven
- Advanced Solid Tumor (22 active studies)
- Breast Cancer (19 active studies)
- Alcohol Use Disorder (15 active studies)
- Acute Myeloid Leukemia (13 active studies)
- Advanced Solid Tumors (12 active studies)
- Heart Failure (11 active studies)
Leading research sponsors in New Haven
- Yale University
- National Cancer Institute (NCI)
- Children's Oncology Group
- Merck Sharp & Dohme LLC
- SWOG Cancer Research Network
Frequently asked questions
How many paid clinical trials are currently recruiting in New Haven?
There are approximately 859 recruiting clinical trials in New Haven, Connecticut listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in New Haven pay participants?
Most recruiting trials in New Haven compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in New Haven?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in New Haven?
The most common conditions under active study in New Haven include Advanced Solid Tumor (22), Breast Cancer (19), Alcohol Use Disorder (15), Acute Myeloid Leukemia (13), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in New Haven?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in New Haven on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in New Haven?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in New Haven?
Recruiting research sites in New Haven include Yale University, Yale Cancer Center, Yale New Haven Hospital, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in New Haven right now?
The largest active categories in New Haven are Cancer & tumors (318), Neurology & pain (42), Cardiovascular (38). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Yale University?
Yale University is located at 310 CEDAR ST, 416A LAUDER HALL, NEW HAVEN, CT 06510-3218. Use the Google Maps link in the intro above to get directions.
How do I contact Yale University?
You can reach Yale University by phone at (203) 785-6843. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.